Cargando…

ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up

PURPOSE: The aim of this study was to examine the expression of ERM (ezrin, moesin) and Rho (RhoA, RhoB and Cdc42) proteins in breast cancer (BC) patients and to investigate the relationship between the sub-cellular localisation of these proteins and clinicopathological characteristics and patient s...

Descripción completa

Detalles Bibliográficos
Autores principales: Halon, Agnieszka, Donizy, Piotr, Surowiak, Pawel, Matkowski, Rafal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656220/
https://www.ncbi.nlm.nih.gov/pubmed/23420497
http://dx.doi.org/10.1007/s13402-013-0125-9
_version_ 1782270002446991360
author Halon, Agnieszka
Donizy, Piotr
Surowiak, Pawel
Matkowski, Rafal
author_facet Halon, Agnieszka
Donizy, Piotr
Surowiak, Pawel
Matkowski, Rafal
author_sort Halon, Agnieszka
collection PubMed
description PURPOSE: The aim of this study was to examine the expression of ERM (ezrin, moesin) and Rho (RhoA, RhoB and Cdc42) proteins in breast cancer (BC) patients and to investigate the relationship between the sub-cellular localisation of these proteins and clinicopathological characteristics and patient survival. METHODS: The expression and specific sub-cellular distribution of the ERM/Rho proteins was analysed by immunohistochemistry in a homogeneous group of 85 stage II ductal BC patients with a follow-up of 15 years. RESULTS: Enhanced immunoreactivity of all analysed proteins was found to be associated with the presence of lymph node metastases (ezrin, P = 0.047, moesin, P = 0.038, RhoA, P = 0.024, RhoB, P = 0.004 and Cdc42, P = 0.047). Nuclear localisation of ezrin was found to correlate with the presence of lymph nodes metastases (P = 0.004) and with histological de-differentiation (P = 0.015). In contrast, we found that the nuclear topography of RhoA and Cdc42, and the perinuclear localisation of RhoB, were strongly associated with a lack of nodal metastases (P = 0.008, P = 0.048, P = 0.001, respectively), whereas a decreased reactivity of RhoA in the stromal compartment of BC tumours was associated with the presence of lymph node metastases (P = 0.011). No relationship was observed between ERM/Rho protein expression and oestrogen receptor (ER), progesterone receptor (PgR) or HER-2 reactivity in the BC cells. Also, ERM/Rho protein expression did not predict patient survival, but RhoB over-expression in the stromal compartment of the tumours was found to be associated with a better prognosis (P = 0.0106). CONCLUSIONS: The ERM/Rho immunoprofile and the assessment of its specific sub-cellular localisation may be instrumental for the prediction of lymph node metastases in ductal BC patients.
format Online
Article
Text
id pubmed-3656220
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-36562202013-05-17 ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up Halon, Agnieszka Donizy, Piotr Surowiak, Pawel Matkowski, Rafal Cell Oncol (Dordr) Original Paper PURPOSE: The aim of this study was to examine the expression of ERM (ezrin, moesin) and Rho (RhoA, RhoB and Cdc42) proteins in breast cancer (BC) patients and to investigate the relationship between the sub-cellular localisation of these proteins and clinicopathological characteristics and patient survival. METHODS: The expression and specific sub-cellular distribution of the ERM/Rho proteins was analysed by immunohistochemistry in a homogeneous group of 85 stage II ductal BC patients with a follow-up of 15 years. RESULTS: Enhanced immunoreactivity of all analysed proteins was found to be associated with the presence of lymph node metastases (ezrin, P = 0.047, moesin, P = 0.038, RhoA, P = 0.024, RhoB, P = 0.004 and Cdc42, P = 0.047). Nuclear localisation of ezrin was found to correlate with the presence of lymph nodes metastases (P = 0.004) and with histological de-differentiation (P = 0.015). In contrast, we found that the nuclear topography of RhoA and Cdc42, and the perinuclear localisation of RhoB, were strongly associated with a lack of nodal metastases (P = 0.008, P = 0.048, P = 0.001, respectively), whereas a decreased reactivity of RhoA in the stromal compartment of BC tumours was associated with the presence of lymph node metastases (P = 0.011). No relationship was observed between ERM/Rho protein expression and oestrogen receptor (ER), progesterone receptor (PgR) or HER-2 reactivity in the BC cells. Also, ERM/Rho protein expression did not predict patient survival, but RhoB over-expression in the stromal compartment of the tumours was found to be associated with a better prognosis (P = 0.0106). CONCLUSIONS: The ERM/Rho immunoprofile and the assessment of its specific sub-cellular localisation may be instrumental for the prediction of lymph node metastases in ductal BC patients. Springer Netherlands 2013-02-19 2013 /pmc/articles/PMC3656220/ /pubmed/23420497 http://dx.doi.org/10.1007/s13402-013-0125-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Halon, Agnieszka
Donizy, Piotr
Surowiak, Pawel
Matkowski, Rafal
ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title_full ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title_fullStr ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title_full_unstemmed ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title_short ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up
title_sort erm/rho protein expression in ductal breast cancer: a 15 year follow-up
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656220/
https://www.ncbi.nlm.nih.gov/pubmed/23420497
http://dx.doi.org/10.1007/s13402-013-0125-9
work_keys_str_mv AT halonagnieszka ermrhoproteinexpressioninductalbreastcancera15yearfollowup
AT donizypiotr ermrhoproteinexpressioninductalbreastcancera15yearfollowup
AT surowiakpawel ermrhoproteinexpressioninductalbreastcancera15yearfollowup
AT matkowskirafal ermrhoproteinexpressioninductalbreastcancera15yearfollowup